Gene · 7030
Papers3,398
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 3,398
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multinucleated tumor cells and micropapillary morphology appear to be predictors of poor prognosis in renal cell carcinoma with papillary and oncocytic features. | Hum Pathol | 2024 | 39489385 | PubTator, text mining | PubMed |
| mTORC1 restricts TFE3 activity by auto-regulating its presence on lysosomes. | Mol Cell | 2024 | 39486419 | PubTator, text mining | PubMed |
| Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma. | World J Urol | 2024 | 39470841 | PubTator, text mining | PubMed |
| TFE3 and TP53 were novel diagnostic biomarkers related to mitochondrial autophagy in chronic rhinosinusitis with nasal polyps. | Front Genet | 2024 | 39440241 | PubTator, text mining | PubMed |
| Large descending colon alveolar soft part sarcoma with ASPL-TFE3 fusion gene: Case report and review of the literature. | Int J Surg Case Rep | 2024 | 39437509 | PubTator, text mining | PubMed |
| TFE3-Rearranged Tumors of the Kidney: An Emerging Conundrum. | Cancers (Basel) | 2024 | 39410016 | PubTator, text mining | PubMed |
| Angiomyolipomatous Lesions of the Nasal Cavity (Sinonasal Angioleiomyoma with Adipocytic Differentiation): A Multi-Institutional Immunohistochemical and Molecular Study. | Head Neck Pathol | 2024 | 39400771 | PubTator, text mining | PubMed |
| TFE3-rearranged RCC with osseous metaplasia found on bone mass densitometry. | Ann Med Surg (Lond) | 2024 | 39359825 | PubTator, text mining | PubMed |
| Integrated stress response plasticity governs normal cell adaptation to chronic stress via the PP2A-TFE3-ATF4 pathway. | Cell Death Differ | 2024 | 39349971 | PubTator, text mining | PubMed |
| Role of the Hippo-YAP/TAZ Pathway in Epithelioid Hemangioendothelioma and its Potential as a Therapeutic Target. | Anticancer Res | 2024 | 39348982 | PubTator, text mining | PubMed |
| Unveiling the link between arsenic toxicity and diabetes: an in silico exploration into the role of transcription factors. | Toxicol Res | 2024 | 39345741 | PubTator, text mining | PubMed |
| Regulation of lysosomes in skeletal muscle during exercise, disuse and aging. | Free Radic Biol Med | 2024 | 39332541 | PubTator, text mining | PubMed |
| An Extremely Rare Case of Primary Malignant Melanoma of the Kidney. | World J Oncol | 2024 | 39328334 | PubTator, text mining | PubMed |
| Malignant Perivascular epithelioid cell tumour of the uterus without TFE3 gene rearrangement: a case report. | BMC Womens Health | 2024 | 39304877 | PubTator, text mining | PubMed |
| Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists. | Virchows Arch | 2024 | 39287823 | PubTator, text mining | PubMed |
| Secondary TFE3-Rearranged Renal Cell Carcinoma in a Chinese Girl Treated for Wilms Tumor: Case Report and Literature Review. | Fetal Pediatr Pathol | 2024 | 39286920 | PubTator, text mining | PubMed |
| Non-autophagic Golgi-LC3 lipidation facilitates TFE3 stress response against Golgi dysfunction. | EMBO J | 2024 | 39284911 | PubTator, text mining | PubMed |
| Expanding the spectrum of fusion partners for cystic TFE3-rearranged renal cell carcinomas: A report of a MAPK1IP1L::TFE3-rearranged renal cell carcinoma. | Hum Pathol | 2024 | 39271027 | PubTator, text mining | PubMed |
| Histopathologic classification and immunohistochemical features of papillary renal neoplasm with potential therapeutic targets. | J Pathol Transl Med | 2024 | 39257049 | PubTator, text mining | PubMed |
| Approach to Diagnosis of TFE3-rearranged Renal Cell Carcinoma in a Limited Resource Setting: A Case Report. | J Kidney Cancer VHL | 2024 | 39206137 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7030/papers?page=17